Chardan lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $15 from $20 and keeps a Buy rating on the shares after the company reported Q2 results and affirmed upcoming catalysts for its LX2006 and LX2020 programs. The firm said it awaits further visibility on focus and strategy, but thinks a non-viral approach could be “quite interesting.” Chardan added that it updated its Lexeo model for Q2 financials, including dilution from the May offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments
- Lexeo Therapeutics price target lowered to $9 from $15 at H.C. Wainwright
- Lexeo Therapeutics Reports Q2 2025 Financial Results
- Lexeo Therapeutics Appoints New Chief Financial Officer
- Lexeo Therapeutics reports Q2 EPS (60c) vs (64c) last year